Your browser doesn't support javascript.
loading
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie, Susanna; Boulware, David R; Lindsell, Christopher J; Stewart, Thomas G; Gentile, Nina; Collins, Sean; McCarthy, Matthew William; Jayaweera, Dushyantha; Castro, Mario; Sulkowski, Mark; McTigue, Kathleen; Thicklin, Florence; Felker, G Michael; Ginde, Adit A; Bramante, Carolyn T; Slandzicki, Alex J; Gabriel, Ahab; Shah, Nirav S; Lenert, Leslie A; Dunsmore, Sarah E; Adam, Stacey J; DeLong, Allison; Hanna, George; Remaly, April; Wilder, Rhonda; Wilson, Sybil; Shenkman, Elizabeth; Hernandez, Adrian F.
Afiliação
  • Naggie S; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Boulware DR; Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Lindsell CJ; Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis.
  • Stewart TG; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Gentile N; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Collins S; Department of Emergency Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
  • McCarthy MW; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Jayaweera D; Department of Medicine, Weill Cornell Medicine, New York, New York.
  • Castro M; Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida.
  • Sulkowski M; Division of Pulmonary, Critical Care and Sleep Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Kansas.
  • McTigue K; Division of Infectious Diseases, Johns Hopkins University, Baltimore, Maryland.
  • Thicklin F; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Felker GM; Stakeholder Advisory Committee, Pittsburgh, Pennsylvania.
  • Ginde AA; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Bramante CT; Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Slandzicki AJ; Department of Emergency Medicine, University of Colorado Denver-Anschutz, Denver.
  • Gabriel A; Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis.
  • Shah NS; Clinical Trials Center of Middle Tennessee, Franklin.
  • Lenert LA; Focus Clinical Research Solutions, Charlotte, North Carolina.
  • Dunsmore SE; NorthShore University HealthSystem, Evanston, Illinois.
  • Adam SJ; Department of Medicine, Medical University of South Carolina, Charleston.
  • DeLong A; National Center for Advancing Translational Sciences, Bethesda, Maryland.
  • Hanna G; Foundation for the National Institutes of Health, Bethesda, Maryland.
  • Remaly A; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Wilder R; Biomedical Advanced Research and Development Authority, Washington, DC.
  • Wilson S; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Shenkman E; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
  • Hernandez AF; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
JAMA ; 328(16): 1595-1603, 2022 10 25.
Article em En | MEDLINE | ID: mdl-36269852

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ivermectina / COVID-19 / Tratamento Farmacológico da COVID-19 / Hospitalização / Anti-Infecciosos Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ivermectina / COVID-19 / Tratamento Farmacológico da COVID-19 / Hospitalização / Anti-Infecciosos Idioma: En Ano de publicação: 2022 Tipo de documento: Article